

to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type.

REMARKS


The amendments to the specification add no new matter. Replacement Tables IV and V, and the paragraphs at pages 50 and 51 have been amended to include SEQ ID NOs. Replacement Tables VII-XX, XXII-XXIV, XXVI-XXIX, XXXa, XXXb, XXXI-XXXIII, XXXV, XXXVI, XXXVIIa and XXXVIIb have been amended to include SEQ ID NOs and to correct the page numbering.

Replacement pages for Tables XXI, XXV, XXXc, XXXIV, and XXXVIII have been corrected for page numbering.

The changes in the page numbering of the replacement pages add no new matter and are the result of page format changes to add SEQ ID NOs. A table indicating the correspondence of the page numbers for replacement Tables VII through XXXVIII to the page numbers of Tables VII through XXXVIII as filed is attached as Appendix A.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JML
SF 1265842 v1